**UConn UPDATE #2: SARS-CoV-2 and COVID-19**

Post-test

**Learning Objectives**

At the end of this continuing education activity, the learner will be able to

* List treatments that are currently being investigated for COVID-19
* Recognize issues of concern related to hydroxychloroquine
* Describe the science behind ABO blood groupings and human susceptibility to viruses

**1. Which of the following statements is TRUE concerning treatments being investigated for COVID-19?**

A. The U.S. Food and Drug Administration has suspended their usual process for drug approval; unpublished data from other countries is sufficient for expedited approval.

B. Clinically, the three drugs that are most likely to be used are hydroxychloroquine, lopinavir/ritonavir, and tocilizumab.

C. The FDA has approved hydroxychloroquine sulfate for any patient regardless of age suspected or laboratory confirmed COVID-19 infection.

**2. Which if the following is a list of FDA-approved uses for hydroxychloroquine?**

A. Malaria, lupus erythematosus, rheumatoid arthritis.

B. Malaria, lupus erythematosus, COVID-19 prophylaxis.

C. Malaria, COVID-19 treatment, rheumatoid arthritis.

**3. A patient who is new to you presents a prescription for hydroxychloroquine 200 mg, #500, with directions to take one tablet every day through June 1, 2020. When you question her, she says her husband is a physician and he wrote it for her and all their family members. What is the BEST way to handle this?**

A. Fill it as a professional courtesy to the physician, who writes many prescriptions for patients in your community.

B. Ask her for the names of all the people who will receive prophylaxis and explain that you want to screen their profiles for potential interactions.

C. Explain that the FDA only allows hydroxychloroquine under narrow circumstances described, and that you are unable to fill it.

**4. Select the statement that is TRUE.**

A. Statisticians and biologists have linked ABO blood groups with many chronic diseases, and suspect blood type may increase risk for some viral infections.

B. Results from a Chinese study suggest that individuals with blood group O seemed to have a higher risk for acquiring COVID-19 than individuals with non-0 blood groups.

C. The largest study of COVID-19 and blood group looked at a large sample of people from around the globe, and factored in conditions that could influences COVID-19’s severity.

**5. Which of the following is a DISADVANTAGE to using passive antibody therapy?**

A. It’s toxicity is high and its specificity is low, and it has potential synergy when combined with other therapies.

B. Successful use of convalescent serum could guide researchers who are working on potential vaccines.

C. A single patient’s antibodies may be insufficient if SARS-CoV-2 viruses have antigenic variation.